{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:04:23Z","timestamp":1791673463875,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-131"],"award-info":[{"award-number":["2022-PUMCH-A-131"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03858-4","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T14:46:43Z","timestamp":1731682003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database"],"prefix":"10.1007","volume":"74","author":[{"given":"Zhaohui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"3858_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.109821","volume":"124","author":"S Tan","year":"2020","unstructured":"Tan S, Li D, Zhu X (2020) Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother 124:109821","journal-title":"Biomed Pharmacother"},{"key":"3858_CR2","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1200\/JCO.2015.63.8049","volume":"34","author":"B Melosky","year":"2016","unstructured":"Melosky B et al (2016) Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. J Clin Oncol 34:1676\u20131688","journal-title":"J Clin Oncol"},{"key":"3858_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237\u2013251","journal-title":"Nat Rev Cancer"},{"key":"3858_CR4","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","volume":"27","author":"D Remash","year":"2021","unstructured":"Remash D et al (2021) Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol 27:5376\u20135391","journal-title":"World J Gastroenterol"},{"key":"3858_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","volume":"4","author":"Y Oshima","year":"2018","unstructured":"Oshima Y, Tanimoto T, Yuji K, Tojo A (2018) EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol 4:1112\u20131115","journal-title":"JAMA Oncol"},{"key":"3858_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12916-022-02713-6","volume":"21","author":"XJ Guo","year":"2023","unstructured":"Guo XJ et al (2023) Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC Med 21:6","journal-title":"BMC Med"},{"key":"3858_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","volume":"14","author":"JJ Lin","year":"2019","unstructured":"Lin JJ et al (2019) Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol 14:135\u2013140","journal-title":"J Thorac Oncol"},{"key":"3858_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105074","volume":"102","author":"SM Ernst","year":"2024","unstructured":"Ernst SM et al (2024) Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis. EBioMedicine 102:105074","journal-title":"EBioMedicine"},{"key":"3858_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","volume":"19","author":"Y Jing","year":"2022","unstructured":"Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L (2022) Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol 19:269\u2013280","journal-title":"Nat Rev Clin Oncol"},{"key":"3858_CR10","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589","journal-title":"Lancet Oncol"},{"key":"3858_CR11","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00262-023-03429-z","volume":"72","author":"Y Shimoda","year":"2023","unstructured":"Shimoda Y et al (2023) Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations. Cancer Immunol Immunother 72:2613\u20132621","journal-title":"Cancer Immunol Immunother"},{"key":"3858_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/annonc\/mdz077","volume":"30","author":"AJ Schoenfeld","year":"2019","unstructured":"Schoenfeld AJ et al (2019) Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 30:839\u2013844","journal-title":"Ann Oncol"},{"key":"3858_CR13","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C et al (2023) First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 389:1839\u20131850","journal-title":"N Engl J Med"},{"key":"3858_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","volume":"18","author":"A Chour","year":"2023","unstructured":"Chour A et al (2023) Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS(G12C)-Mutant Lung Cancer. J Thorac Oncol 18:1408\u20131415","journal-title":"J Thorac Oncol"},{"key":"3858_CR15","volume":"2","author":"P Begum","year":"2021","unstructured":"Begum P, Goldin RD, Possamai LA, Popat S (2021) Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report. JTO Clin Res Rep 2:100213","journal-title":"JTO Clin Res Rep"},{"key":"3858_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA Janne","year":"2022","unstructured":"Janne PA et al (2022) Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. N Engl J Med 387:120\u2013131","journal-title":"N Engl J Med"},{"key":"3858_CR17","doi-asserted-by":"crossref","unstructured":"Passiglia, F. et al. (2024) Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. Lung Cancer 187 107444","DOI":"10.1016\/j.lungcan.2023.107444"},{"key":"3858_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105074","volume":"102","author":"SM Ernst","year":"2024","unstructured":"Ernst SM et al (2024) Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis. EBioMedicine 102:105074","journal-title":"EBioMedicine"},{"key":"3858_CR19","volume":"4","author":"M Sisi","year":"2023","unstructured":"Sisi M et al (2023) Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors. JTO Clin Res Rep 4:100563","journal-title":"JTO Clin Res Rep"},{"key":"3858_CR20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1001\/jamaoncol.2017.4606","volume":"4","author":"C Tang","year":"2018","unstructured":"Tang C, Jiang W, Yap TA (2018) Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword. JAMA Oncol 4:1116\u20131117","journal-title":"JAMA Oncol"},{"key":"3858_CR21","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/2326-6066.CIR-18-0193","volume":"6","author":"PH Lizotte","year":"2018","unstructured":"Lizotte PH et al (2018) A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunol Res 6:1511\u20131523","journal-title":"Cancer Immunol Res"},{"key":"3858_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00262-020-02714-5","volume":"70","author":"H Adderley","year":"2021","unstructured":"Adderley H, Blackhall FH, Lindsay CR (2021) Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer. Cancer Immunol Immunother 70:589\u2013595","journal-title":"Cancer Immunol Immunother"},{"key":"3858_CR23","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.21037\/tlcr-21-455","volume":"10","author":"X Zhang","year":"2021","unstructured":"Zhang X et al (2021) Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1\/PD-L1 therapy. Transl Lung Cancer Res 10:3191\u20133202","journal-title":"Transl Lung Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03858-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03858-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03858-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:49:12Z","timestamp":1738259352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03858-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3858"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03858-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since the FAERS database is accessible to the public and patient records are anonymized and de-identified, ethical clearance and informed consent are not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"25"}}